Wall Street analyst estimates for Cadrenal Therapeutics, Inc. Common Stock (CVKD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.91 | ||
| 2026-08-13 | $-1.14 | $-1.42 | +19.7% |
| 2026-05-07 | $-1.04 | $-1.51 | +31.1% |
| 2026-03-31 | $-1.41 | $-1.17 | -20.5% |
| 2025-11-10 | $-1.31 | $-1.55 | +15.5% |
| 2025-08-11 | $-1.87 | $-1.60 | -16.9% |
| 2025-05-08 | $-2.09 | $-1.64 | -27.4% |
| 2025-03-13 | $-2.74 | $-1.71 | -60.2% |
Valuation Ratios
| Price / Book | 0.77 |
| EV / EBITDA | -0.16 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1266 | 0 | 0 | 0 |
| Gross Profit | -$1266 | 0 | 0 | 0 |
| Research & Development | $392859 | $4.1M | $4.2M | $4.1M |
| Selling, General & Admin | $2.3M | $3.5M | $6.8M | $9.4M |
| Operating Expenses | $2.7M | $7.6M | $11.0M | $13.5M |
| Operating Income | -$2.7M | -$7.6M | -$11.0M | -$13.5M |
| EBITDA | -$6.6M | -$8.3M | -$10.6M | -$13.2M |
| Interest Expense | $107105 | $17101 | 0 | 0 |
| Pre-tax Income | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
| Income Tax | 0 | 0 | 0 | 0 |
| Net Income | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
| EPS | $-8.66 | $-9.63 | $-8.73 | $-6.64 |
| EPS (Diluted) | $-8.66 | $-9.63 | $-8.73 | $-6.64 |
| Shares Outstanding (Diluted) | $775638 | $868183 | $1.2M | $2.0M |
Price
| Price | $1.08 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLGN · IBIO · ITRM · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of CVKD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks